Clinical Trial Update: A Dose-finding Study of CC-90009 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-risk Myelodysplastic Syndromes [Phase 1]

View source ↗

Summary

A Phase 1 dose-finding study of CC-90009 in adults with relapsed or refractory acute myeloid leukemia or relapsed/refractory higher-risk myelodysplastic syndrom…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndromes

Drugs mentioned

• CC-90009

Snippet

Sponsor: Celgene | Conditions: Leukemia, Myeloid, Acute, Myelodysplastic Syndromes | Phase 1 | Status: TERMINATED | Results posted: 2025-06-12